Clinical Trials
16
Active:0
Completed:1
Trial Phases
5 Phases
Phase 1:2
Phase 2:7
Phase 3:3
+2 more phases
Drug Approvals
1
PHILIPPINES:1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
Phase 2
7 (43.8%)Phase 3
3 (18.8%)Phase 4
3 (18.8%)Phase 1
2 (12.5%)Not Applicable
1 (6.3%)A Comparative Study of the Pharmacokinetics of SIM0718 Injection in Healthy Adult Subjects in China
Phase 1
Not yet recruiting
- Conditions
- Healthy Adult Subjects
- Interventions
- Drug: Rademikibart injectionDrug: CBP-201 injection
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Simcere Pharmaceutical Co., Ltd
- Target Recruit Count
- 178
- Registration Number
- NCT06701149
SIM0718 Treatment of Asthma Clinical Study
Phase 3
Recruiting
- Conditions
- Asthma; Eosinophilic
- Interventions
- Drug: SIM0718 injection of placebo
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Simcere Pharmaceutical Co., Ltd
- Target Recruit Count
- 418
- Registration Number
- NCT06488755
- Locations
- 🇨🇳
China Japan Friendship Hospital, Beijing, Beijing, China
A Study to Evaluate the Efficacy and Safety of SIM0718 in Adult and Adolescent Patients With Moderate to Severe Atopic Dermatitis
Phase 3
Not yet recruiting
- Conditions
- Atopic Dermatitis
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Simcere Pharmaceutical Co., Ltd
- Target Recruit Count
- 250
- Registration Number
- NCT06477835
Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients
Phase 2
Recruiting
- Conditions
- Post-stroke Cognitive Impairment
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-03-18
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Simcere Pharmaceutical Co., Ltd
- Target Recruit Count
- 200
- Registration Number
- NCT06315231
- Locations
- 🇨🇳
Taihe County People's Hospital, Fuyang, Anhui, China
🇨🇳Hefei First People's Hospital, Hefei, Anhui, China
🇨🇳The First Affiliated Hospital of USTC Anhui Provincial Hospital, Hefei, Anhui, China
The Efficacy and Safety of Edaravone Dexborneol Sequential Therapy in the Treatment of Patients With AIS
Phase 3
Not yet recruiting
- Conditions
- Subjects With Acute Ischemic Stroke
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Simcere Pharmaceutical Co., Ltd
- Target Recruit Count
- 880
- Registration Number
- NCT06176781
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found